Autosomal monosomies among 24,262 consecutive cytogenetic studies: Prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities

American Journal of Hematology

Volumn 86, Issue 4, 2011, Pages 353-356

  Raza, Sania ^a   Tahernazerhussain, Fareeda ^a   Patnaik, Mrinal ^a   Knudson, Ryan ^b   Van Dyke, Daniel ^b   Tefferi, Ayalew ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME 20; CHROMOSOME 21; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; HUMAN; MONOSOMY; MONOSOMY 12; MONOSOMY 13; MONOSOMY 17; MONOSOMY 18; MONOSOMY 20; MONOSOMY 21; MONOSOMY 5; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CYTOGENETIC ANALYSIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROMES; PREVALENCE; PRIMARY MYELOFIBROSIS; PROGNOSIS; YOUNG ADULT;

EID: 79953047317     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21988     Document Type: Article

References (28)

1. Smith ML, Hills RK, Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011; 25: 39-51.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
3. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
4. Lowenberg B. Acute myeloid leukemia: The challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008: 1-11.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
6. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica, 2010 Dec 6. [Epub ahead of print]
7. Santos FP, Kantarjian H, Garcia-Manero G, et al. The search for better prognostic models in myelodysplastic syndromes. Curr Hematol Malig Rep 2011; 6: 13-21.
8. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer 2008; 113: 1351-1361.
9. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
10. Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1, 029 patients with primary myelodysplastic syndromes: A report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008; 113: 3331-3340.
11. Sole F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 2000; 108: 346-356.
12. Wiktor A, Rybicki BA, Piao ZS, et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27: 11-16.
13. Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 3285-3291.
14. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-3932.
15. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
16. Gangat N, Caramazza D, Vaidya R, et al. DIPSS-Plus: A refined dynamic international prognostic scoring system (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol 2011; 29: 392-397.
17. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia 2011; 25: 82-88.
18. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761.
19. Guglielmelli P, Barosi G, Specchia G, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
20. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302-1309.
21. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.
22. Medeiros BC, Othus M, Fang M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: The Southwest Oncology Group experience. Blood 2010; 116: 2224-2248.
23. Oran B, Dolan M, Cao Q, et al. Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in AML Patients. Biol Blood Marrow Transplant 2011; 17: 356-364.
24. Patnaik MM, Hanson CA, Hodnefield JM, et al. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2010.
25. Vaidya R, Caramazza D, Begna K, et al. Monosomal Karyotype In primary myelofibrosis is prognostically worse than otherwise unfavorable karyotype. ASH Annual Meeting Abstracts; 116: 3069-3070.
26. Dewald GW, Broderick DJ, Tom WW. The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 1985; 18: 1-10.
27. Shaffer LGSM, Campbell LJ, editors. An International System for Human Cytogenetic Nomenclature, S Karger, Basel 2009.
28. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.